Dubavo SA
8.1 FTEDubavo reported total assets of €3.97m at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Dec 2025), with 8.1 full-time equivalents.
The score of Dubavo shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -16 % Total assets -10 % Headcount (avg FTE) -7 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dubavo's annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 19 Dec 2025
- Year ended 30 Jun 2024filed on 17 Dec 2024
- Year ended 30 Jun 2023filed on 09 Feb 2024
- Year ended 31 May 2022filed on 11 Jan 2023
- Year ended 30 Jun 2021filed on 27 Jan 2022
Dubavo's financial analysis
- Solvency67.8%sector median: 45.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dubavo
Dubavo's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0437.634.801
- VAT number
- BE0437634801
- Peppol
- Registered · 0208:0437634801 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 12 May 1989
- Registered office
- 8647 Lo-Reninge
- Size
- Micro · 8.1 FTE
- Latest accounts
- 2025 · filed on 19 Dec 2025
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Dubavo (SA) has been based in Lo-Reninge since 1989, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net loss of 69,927 € and equity of €2.69m; its revenue is not published. With 8.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 67.8%, above the median of its sector (45.8%).
Companies similar to Dubavo
Companies in the same business, of comparable size and area, outside its group.
- Servicov Wholesale of pharmaceutical and medical goods Ghent · balance sheet €3.54m
- LPG Benelux Wholesale of pharmaceutical and medical goods Drogenbos · balance sheet €3.55m
- ScarPro Wholesale of pharmaceutical and medical goods Aalter · balance sheet €6.98m
- Euromedix Point OF Care Wholesale of pharmaceutical and medical goods Leuven · balance sheet €3.24m
- Etablissements Henri Nootens Wholesale of pharmaceutical and medical goods Schaerbeek · balance sheet €5.13m
- GHX Europe Wholesale of pharmaceutical and medical goods Brussels · balance sheet €2.81m
- Menarini Stemline Benelux NV/SA Wholesale of pharmaceutical and medical goods Machelen (Brab.) · balance sheet €2.57m
- Celyntra Therapeutics Wholesale of pharmaceutical and medical goods Mont-Saint-Guibert · balance sheet €8.20m
Frequently asked questions about Dubavo
What is the revenue of Dubavo?
Dubavo files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Dubavo?
In Belgium, the VAT number is the company number prefixed with BE: BE0437634801 for Dubavo, if the company is VAT-registered. Its company number (CBE) is 0437.634.801.
Where is the registered office of Dubavo?
According to the CBE register, the registered office of Dubavo is in 8647 Lo-Reninge.
What is the equity of Dubavo?
At the close of the 2025 financial year, the equity of Dubavo amounts to 2,690,798 €, a solvency of 67.8% of total assets.
How many people work at Dubavo?
8.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Dubavo?
The register lists 6 active mandates at Dubavo. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dubavo
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →